- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06153966
En undersøgelse for at vurdere sikkerhed, tolerabilitet, farmakokinetik og farmakodynamik af ION717.
Et fase 1/2a-studie til evaluering af sikkerhed, tolerabilitet, farmakokinetik og farmakodynamik af intratekalt administreret ION717 hos patienter med prionsygdom
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a first-in-human, multi-center study in participants with prion disease. The study will consist of a screening period of up to 6 weeks, a 30-week treatment period, a 142-week open-label extension period and a 32-week post-treatment period. Multiple dose levels will be tested.
The trial consists of three Regimens. Participants in Regimens 1 and 2 received multiple doses of study drug (ION717 and placebo) during the 30-week double-blind treatment period; the order of doses (i.e. whether a given dose was ION717 or placebo) was blinded. Regimen 3 is open label.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Parkville, Australien, 3050
- Royal Melbourne Hospital
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 2B4
- McGill University Health Centre
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10016
- NYU Langone Health
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- University Hospitals Cleveland Medical Center
-
-
-
-
-
Paris, Frankrig, 75013
- Hôpital Universitaire Pitié Salpêtrière
-
-
-
-
-
Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Milan, Italien, 20133
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
-
-
-
-
Isesaki-shi
-
Gunma, Isesaki-shi, Japan, 372-0006
- Mihara Memorial Hospital
-
-
Kodaira-shi
-
Tokyo, Kodaira-shi, Japan, 187-8551
- National Center of Neurology and Psychiatry
-
-
Shimonoseki-shi
-
Yamaguchi, Shimonoseki-shi, Japan, 751-0826
- Neuromuscular Center Yoshimizu Hospital
-
-
-
-
-
Barcelona, Spanien, 08036
- Hospital Clinic De Barcelona
-
-
-
-
-
Göttingen, Tyskland, 37075
- University Medical Center Göttingen
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria
- A confirmed diagnosis of probable or definite prion disease.
- Early-stage prion disease at the time of Screening.
- Willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits.
- Patients must have a caregiver who is ≥ 18 years old and who is able and willing to facilitate the patient's involvement, to the best of their ability, for the duration of the trial; caregivers must also be able and willing to provide information about themselves and the patient for the duration of the trial.
- Aged ≥ 18 at the time of informed consent.
Key Exclusion Criteria
- Clinically significant abnormalities in medical history, laboratory tests or physical examination that would render a patient unsuitable for inclusion.
- Any contraindication or unwillingness to undergo an MRI.
- Obstructive hydrocephalus, presence of a functional ventriculoperitoneal shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter.
- Known brain or spinal disease that would interfere with the LP process, CSF circulation or safety assessment.
- Have any other condition, which, in the opinion of the Investigator would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ION717 + Placebo, Regimen 1
Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 142-week open-label extension period. |
ION717 will be administered by IT injection. Placebo-matching ION717 will be administered by IT injection. |
|
Eksperimentel: ION717 + Placebo, Regimen 2
Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 142-week open-label extension period. |
ION717 will be administered by IT injection. Placebo-matching ION717 will be administered by IT injection. |
|
Eksperimentel: ION717, Regimen 3
Participants will receive multiple doses of ION717 during the 30-week treatment period and the 142-week open-label extension period. |
ION717 will be administered by IT injection. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst af behandlingsudspringende bivirkninger.
Tidsramme: Baseline op til uge 33
|
Baseline op til uge 33
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Maksimal observeret plasmakoncentration (Cmax) af ION717
Tidsramme: på dag 1 og uge 9
|
på dag 1 og uge 9
|
|
Areal under plasmakoncentration-tidskurven (AUC) for ION717
Tidsramme: på dag 1 og uge 9
|
på dag 1 og uge 9
|
|
Halveringstid (t1/2λz) af ION717 i plasma
Tidsramme: på dag 1 og uge 9
|
på dag 1 og uge 9
|
|
Mængde af ION717 udskilt i urin
Tidsramme: Efter dosis på dag 1
|
Efter dosis på dag 1
|
|
Cerebrospinalvæske (CSF) Koncentration af ION717
Tidsramme: Før dosis og på flere punkter efter dosis op til uge 33
|
Før dosis og på flere punkter efter dosis op til uge 33
|
|
Procent ændring fra baseline i prionprotein (PrP) koncentration i CSF
Tidsramme: Før dosis og på flere punkter efter dosis op til uge 33
|
Før dosis og på flere punkter efter dosis op til uge 33
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ION717-CS2
- 2023-503355-98 (EudraCT nummer)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .